184878-97-5

Basic information

• Product Name: Acetic acid, [4-(1-methylethyl)phenoxy]-, methyl ester
• CAS NO: 184878-97-5
• Molecular Formula: C12H16O3
• Molecular Weight: 208.257
• Mol File: 184878-97-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Acetic acid, [4-(1-methylethyl)phenoxy]-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Acetic acid, [4-(1-methylethyl)phenoxy]-, methyl ester(184878-97-5)
• EPA Substance Registry System: Acetic acid, [4-(1-methylethyl)phenoxy]-, methyl ester(184878-97-5)

Safety Data

• Hazardous Substances Data: 184878-97-5(Hazardous Substances Data)

Upstream product

• 99-89-8 4-Isopropylphenol 
• 96-32-2 bromoacetic acid methyl ester 
• 96-34-4 methyl chloroacetate 

Downstream Products

• 443905-53-1 2-(4-isopropylphenoxy)acetohydrazide 
• 1643-16-9 2-(4-isopropylphenoxy)acetic acid 
• 184878-98-6 2-(4-Isopropyl-phenoxy)-3-phenyl-propionic acid methyl ester 

Relevant articles and documents

Staphylococcus aureus rnpa inhibitors: Computational-guided design, synthesis and initial biological evaluation

Antibiotic resistance is spreading worldwide and it has become one of the most important issues in modern medicine. In this context, the bacterial RNA degradation and processing machinery are essential processes for bacterial viability that may be exploited for antimicrobial therapy. In Staphylococcus aureus, RnpA has been hypothesized to be one of the main players in these mech-anisms. S. aureus RnpA is able to modulate mRNA degradation and complex with a ribozyme (rnpB), facilitating ptRNA maturation. Corresponding small molecule screening campaigns have recently identified a few classes of RnpA inhibitors, and their structure activity relationship (SAR) has only been partially explored. Accordingly, in the present work, using computational modeling of S. aureus RnpA we identified putative crucial interactions of known RnpA inhibitors, and we used this information to design, synthesize, and biologically assess new potential RnpA inhibitors. The present results may be beneficial for the overall knowledge about RnpA inhibitors belonging to both RNPA2000-like thiosemicarbazides and JC-like piperidine carboxamides molecular classes. We evaluated the importance of the different key moieties, such as the dichlorophenyl and the piperidine of JC2, and the semithiocarbazide, the furan, and the i-propylphenyl ring of RNPA2000. Our efforts could provide a foundation for further computational-guided investigations.

Glucose transport-enhancing and hypoglycemic activity of 2-methyl-2- phenoxy-3-phenylpropanoic acids

A series of 2-phenoxy-3-phenylpropanoic acids has been prepared which contains many potent hypoglycemic agents as demonstrated by assessing glucose lowering in ob/ob mice. Some compounds (32, 33, 59) normalize plasma glucose in this diabetic model at doses of approximately 1 mg/kg. The mechanism of action of these drugs may involve enhanced glucose transport, especially in fat cells, but the compounds do not stimulate GLUT4 translocation and do not increase the levels of GLUT1 or GLUT4 in vivo. Thus, these compounds may enhance the intrinsic activity of the glucose transporter GLUT1 or GLUT4. Some compounds also modestly decrease hepatocyte gluconeogenesis in vitro, but this is not likely to be a major contributor to the hypoglycemic effect observed in vivo. Likewise, a modest decrease in food consumption observed with some of these compounds was shown by a pair-feeding experiment not to be the primary cause of the hypoglycemia observed.